OBJECTIVE To identify and evaluate the risk signals of tislelizumab in non-small-cell lung cancer(NSCLC)pa-tients,so as to provide basis for future management of irAEs and better tumor immunotherapy in NSCLC patients.METHODS The clinical data of NSCLC patients who received tislelizumab in Peking University People's Hospital from April 2021 to April 2023 were retrospectively analyzed.The occurrence of irAEs during tislelizumab treatment was observed,the incidence of irAEs was summarized,and the clinical features of irAEs and non-irAEs groups were compared.RESULTS Sixty-eight NSCLC patients received tislelizum-ab,of whom 22(32.35％)developed 32 irAEs.The main manifestations were pulmonary toxicity(17.65％),skin toxicity(11.76％),endocrine toxicity(5.88％),gastrointestinal toxicity(4.41％),cardiovascular toxicity(4.41％),and hematological toxicity(2.94％).The median duration of irAEs was 79 d(1-706 d).Thirteen cases(59.09％)were treated with glucocorticoids.Comparison of the clinical characteristics of irAEs group and non-irAEs group showed that the incidence of irAEs in patients with hepat-ic insufficiency was higher(P＜0.05),the other differences were not statistically significant(P＞0.05).CONCLUSION irAEs involve multiple systems/organs,so attention should be paid to the management of immune-related toxicity,timely detection,and treat-ment of irAEs,to achieve better effects of tumor immunotherapy.
关键词
免疫相关不良反应/真实世界研究/替雷利珠单抗/非小细胞肺癌
Key words
immune-related adverse event/real-world study/tislelizumab/non-small cell lung cancer
维普
万方数据